SCHEMBL7710152

SCHEMBL7710152

O=C(Oc1c2cccc(Cl)c2cc2cccc(Cl)c12)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.43
KMT2A Q03164 7/20 0.43
MEN1 O00255 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 4/20 0.42
GAA P10253 3/20 0.42
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
JAK2 O60674 1/20 0.40
USP2 O75604 1/20 0.40
ESR1 P03372 1/20 0.40
ALOX15 P16050 1/20 0.40
ESR2 Q92731 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PKM P14618 2/20 0.39
HTT P42858 4/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7712641 0.87 KMT2A (0.47) MAPTKMT2AMEN1LMNAGAA
SCHEMBL29371981 0.84 KMT2A (0.45) MAPTKMT2AMEN1LMNAGAA
SCHEMBL7712652 0.82 MAPT (0.46) MAPTKMT2AMEN1TDP1GAA
SCHEMBL8837615 0.80 KMT2A (0.55) MAPTKMT2AMEN1TDP1LMNA
SCHEMBL29371006 0.77 NPC1 (0.47) MAPTKMT2AMEN1TDP1LMNA
SCHEMBL7707836 0.76 KDM4E (0.48) MAPTKMT2ATDP1GAANPSR1
SCHEMBL9161406 0.76 LMNA (0.50) MAPTKMT2AMEN1TDP1LMNA
SCHEMBL7713950 0.75 ESR1 (0.43) KMT2AMEN1TDP1LMNAGAA
SCHEMBL29368995 0.74 KMT2A (0.48) MAPTKMT2AMEN1TDP1LMNA
SCHEMBL27615313 0.74 KMT2A (0.44) MAPTKMT2AMEN1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6369246-B2 ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS DR. KEITH CHAN, GLOBOASIA, LLC 2002-04-09 US disclosed
US-20010018539-A1 Synthesis and pharmaceuticals of novel 9-substituted-1, 5-dichloroanthracene analogs CHAN, KEITH 2001-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018539-A1 Synthesis and pharmaceuticals of novel 9-substituted-1, 5-dichloroanthracene analogs C3AR1, C5AR2, TLR2 MAPT 4591/4885KMT2A 804/4885MEN1 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.